Mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer.
BACKGROUND
Chemotherapy can be used to palliate the symptoms in patients with advanced non-small cell lung cancer.


METHODS
Twenty-four chemo-naive patients with stage IIIB and IV non-small cell lung cancer were treated with the MIC regimen (mitomycin, ifosfamide and cisplatin).


RESULTS
The overall response rate was 33% (partial response) and median duration of response was 7 months (range 5 to 10 months). At median follow-up of 26 months, the median survival was 8 months, and 1-year survival was 29%. Toxicities were tolerable.


CONCLUSIONS
This appears to be a reasonable regimen for palliating advanced non-small cell lung cancer.
Soh
L T
LT
Department of Medical Oncology, Singapore General Hospital, Singapore.
Tan
E H
EH
Ang
P T
PT
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000009:adverse effects; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage* / Q000009:adverse effects; D009367:Neoplasm Staging; D010166:Palliative Care; D012074:Remission Induction; D015996:Survival Rate
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D008937:Mitomycins; D002945:Cisplatin; D007069:Ifosfamide